Physicians' Academy for Cardiovascular Education

What is the clinical evidence for the benefits of GLP-1RAs?

5 Things a cardiologist needs to know about GLP-1 RA

*NEW* Subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Toronto, ON, Canada

Video navigation menu

  • Pathophysiology of CVD in diabetes  00:29
  • Clinical trials led to changes in European and US treatment guidelines  01:50
  • CV events of the various trials more in detail 07:55
  • How do GLP-1RAs reduce ischemic events? 10:51
  • Ongoing clinical trials with GLP-1RA 13:07

Transcript

Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2DM and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.

Faculty

Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, Ont, Canada

Disclosures

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Or listen to the podcast

Share this page with your colleagues and friends: